CDK4/6 inhibitors have rapidly changed the treatment landscape for ER+/HER2− metastatic breast cancer patients in combination with endocrine therapy, which significantly lengthened progression-free survival (PFS) and overall survival (OS) [8]. This evidence concerns the gene ESR1 and breast carcinoma.